ショートコース
ショートコースは、インストラクショナルかつインタラクティブに設計されており、また、特定のトピックに関する詳細な情報を提供します。参加者とインストラクターとの1対1のやり取りが可能であり、メインプレゼンテーションではカバーされない、より技術的な側面の説明を容易にします。
ショートコースは対面式参加のみでの提供です
2023年5月14日(日) 2:00 - 5:00 pm
SC1: Antibody Drug Discovery: From Target to Lead
SC1:抗体創薬 - ターゲットツーリード(T2L)から
Antibody Drug Discovery: From Target to Lead
Zhiqiang An, PhD, Professor, Molecular Medicine, University of Texas Health Science Center at Houston
Topics to be covered include:
- Different sources of antibodies (animals, libraries, and B-cells)
- Various antibody-based drug modalities (ADC, bispecific, naked antibody, and CAR T)
- Antibody engineering (affinity maturation, humanization, isotypes, and formats)
- Target selection and design including complex membrane proteins (GPCRs, ion channels, transporters, and membrane-bound enzymes)
- Case studies
INSTRUCTOR BIOGRAPHIES:
Zhiqiang An, PhD, Professor, Molecular Medicine, University of Texas Health Science Center at Houston
SC2: Introduction to Lipid Nanoparticle Characterization and Formulation
SC2:脂質ナノ粒子の特性評価と構築入門
Introduction to Lipid Nanoparticle Characterization and Formulation
INSTRUCTOR BIOGRAPHIES:
Jan Jezek, CSO, Arecor, United Kingdom
SC3: In silico and Machine Learning Tools for Antibody Design and Developability Predictions
SC3:抗体設計と開発可能性予想へのin silicoと機械学習ツール
Structure and Machine Learning (ML) Guided Tools for Antibody Design and Developability Predictions
Philip M. Kim, PhD, Professor, Molecular Genetics & Computer Science, University of Toronto
Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.
Christopher J. Langmead, PhD, Director of Digital Biologics Discovery, Amgen
Topics to be covered include:
- Revealing a Global Biologics Research Informatics Platform integrating in silico prediction and lab experiment data to fast-forward biologics drug design and development
- Putting the platform into practice with biologic discovery use cases
- Elucidating process development best practices with use cases from Takeda
INSTRUCTOR BIOGRAPHIES:
Philip M. Kim, PhD, Professor, Molecular Genetics & Computer Science, University of Toronto
Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.
Christopher J. Langmead, PhD, Director of Digital Biologics Discovery, Amgen
SC4: An Introduction to Protein Degraders: A Focus on PROTACs
SC4:プロテインデグレーダー入門 - PROTAC(タンパク質分解誘導キメラ分子)への注目
An Introduction to Protein Degraders: A Focus on PROTACs
John Erve, PhD, Senior Principal Scientist, Jerve Scientific Consulting
Topics to be Covered:
- Advantages of PROTACs compared to small molecules
- Importance of ternary complex formation
- Strategies to enhance PROTAC selectivity
- Why proteomics is essential for developing PROTACs
- Challenges of developing PROTACs in the context of Bro5
- Safety issues unique to PROTACs
INSTRUCTOR BIOGRAPHIES:
John Erve, PhD, Senior Principal Scientist, Jerve Scientific Consulting
2023年5月16日(火) 6:30 - 9:00 pm
SC5: Introduction to Gene Therapy Product Manufacturing and Analytics
SC5:遺伝子治療製品製造と分析入門
Introduction to Gene Therapy Product Manufacturing and Analytics
Claire Davies, PhD, Associate Vice President, Bioanalytics, Sanofi
Scott Dooley, Senior Scientist, Analytical Development, Sanofi
Topics to be covered include:
- Overview of Manufacturing for Gene Therapy Products and Parallels with Protein Therapeutics
- Analytical Development Strategies
- Phase-Appropriate Control Strategy
- Regulatory Guidance and Expectations for Gene Therapy Products
- Specific Challenges in Comparison to Protein Therapeutics
- Potential for Leveraging Platforms and Benefits
- Interactive Workshop on Developing a Control Strategy
- Non-Viral Vectors Including Lipid Nanoparticles
INSTRUCTOR BIOGRAPHIES:
Claire Davies, PhD, Associate Vice President, Bioanalytics, Sanofi
Scott Dooley, Senior Scientist, Analytical Development, Sanofi
SC6: Developability of Bispecific Antibodies
SC6:二重特異性抗体の開発可能性
Developability of Bispecific Antibodies
Nimish Gera, PhD, Vice President, Biologics, Mythic Therapeutics
Topics to be Covered Include:
- Introduction to bispecifics and bispecific formats
- Therapeutic applications of bispecific antibodies
- Developability of bispecifics
- Case study: discovery and development of an FDA-approved bispecific antibody
INSTRUCTOR BIOGRAPHIES:
Nimish Gera, PhD, Vice President, Biologics, Mythic Therapeutics
SC7: Use and Troubleshooting of Eukaryotic Expression Systems
SC7:真核生物発現システムの使用とトラブルシューティング
Use and Troubleshooting of Eukaryotic Expression Systems
Richard Altman, MS, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific
Henry C. Chiou, PhD, Senior Director General Manager, Biosciences, Thermo Fisher Scientific
Dominic Esposito, PhD, Director, Protein Sciences, Frederick National Laboratory
6:30 pm Opening Remarks/Introductions
Richard Altman, MS, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
INSTRUCTOR BIOGRAPHIES:
Richard Altman, MS, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific
Henry C. Chiou, PhD, Senior Director General Manager, Biosciences, Thermo Fisher Scientific
Dominic Esposito, PhD, Director, Protein Sciences, Frederick National Laboratory
SC8: CAR T Cells: Improving Safety While Retaining Therapeutic Activity
SC8:CAR T細胞 - 治療活性を保持する間の安全性の向上
CAR T Cells: Improving Safety While Retaining Therapeutic Activity
Nasheed M. Hossain, MD, Assistant Professor of Medicine, University of Pennsylvania - Perelman School of Medicine, Department of Medicine - Division of Hematology/Oncology, Cell Therapy & Transplant Program
Michael I. Nishimura, PhD, Professor, Surgery, Loyola University Chicago
Rimas J. Orentas, PhD, Scientific Director, Caring Cross, Inc.; Professor, University of Washington School of Medicine
- Considerations for target selection and results in the clinic using CAR T cells against that target
- Adverse events encountered in patients treated with CAR T cells
- Manufacturing hurdles and practical considerations for CAR T products
- New approaches for making better CAR T products
INSTRUCTOR BIOGRAPHIES:
Nasheed M. Hossain, MD, Assistant Professor of Medicine, University of Pennsylvania - Perelman School of Medicine, Department of Medicine - Division of Hematology/Oncology, Cell Therapy & Transplant Program
Michael I. Nishimura, PhD, Professor, Surgery, Loyola University Chicago
Rimas J. Orentas, PhD, Scientific Director, Caring Cross, Inc.; Professor, University of Washington School of Medicine
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。
2023年 プログラム
View By:







